PHARPharming Group N.V.vs its industry peers
A metric-by-metric comparison of Pharming Group N.V. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PHARThis | $7.8B#1 | — | — | 20.6x#1 | 26.6%#1 | 124.1%#2 | 6.9%#2 | — | — | — | -23.8%#3 | — |
| OTLC | — | — | — | — | — | 5610.7%#1 | -4552.3%#4 | 94.2%#1 | -0.8%#2 | — | — | — |
| PAHC | — | 14.4x#1 | — | — | 17.1%#2 | 106.6%#3 | 12.8%#1 | 25.9%#2 | 14.8%#1 | — | -9.3%#2 | — |
| PBM | $13M#2 | — | — | — | — | 102.0%#4 | — | — | — | — | -75.4%#4 | — |
| PBMWW | $68569#4 | — | — | — | — | 102.0%#4 | — | — | — | — | 2.7%#1 | — |
| PCYN | — | — | — | — | 6.4%#3 | -579.0%#8 | -4.6%#3 | -14.9%#3 | -10.5%#3 | — | — | — |
| PKTX | — | — | — | — | — | -8.1%#7 | — | -132.1%#5 | — | — | — | — |
| PRFX | $855531#3 | — | 0.1x#1 | 50.3x#2 | — | 65.6%#6 | -30129.4%#5 | -58.8%#4 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice